logo
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

Yahoo14-05-2025

Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25
Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash
Conference call and webcast to be held today, May 14th, at 8:30 AM EDT
NEW YORK, May 14, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended March 31, 2025.
Conference Call and Webcast
The webcast will take place on Wednesday, May 14, 2025, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
Business Highlights
"We are now better positioned than ever to capitalize on EsoGuard's significant clinical and commercial opportunity," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "We continue to make strong progress on multiple fronts – expanding our cash-pay and contracted programs targeting concierge medicine practices and self-insured employers, while also gaining traction with regional commercial insurers for EsoGuard coverage. With additional capital secured, we have extended our operational runway well beyond key upcoming reimbursement milestones, including Medicare. This positions us to accelerate commercialization efforts once these milestones are achieved."
Processed 3,034 EsoGuard® Esophageal DNA Tests in 1Q25,
Recognized $0.8 million in EsoGuard revenue for 1Q25.
Strengthened balance sheet with two common stock offerings with strategic long-term investors, netting approximately $30.6 million in proceeds; ended 1Q25 with over $40 million in proforma cash and extended runway well into 2026 and past key milestones.
Launched "Embrace the Future" campaign, showcasing the EsoCheck® Cell Collection Device's groundbreaking Collect+Protect™ Technology relative to antiquated sponge-on-a-string devices.
Partnered with a major health system to launch a comprehensive EsoGuard esophageal precancer testing program, expanding access to at-risk patients across the health system's digestive health, primary care, and concierge medicine programs.
Continued to gain traction in cash-pay concierge medicine and employer markets sales channels, both of which are expected to begin driving contractually-guaranteed revenue in 2H25.
NCI-sponsored study demonstrated EsoGuard effectively detects esophageal precancer in at-risk patients without GERD, supporting expanded indication and may increase market opportunity by as much as 70%.
Granted a U.S. patent for key technology underlying EsoGuard, adding to an already robust intellectual property portfolio. The patent covers proprietary methods using methylation of the SqBE18 (CCNA1) gene to detect esophageal precancer and cancer
Financial Results
For the three months ended March 31, 2025, EsoGuard related revenues were $0.8 million. Operating expenses were approximately $13.3 million, which included stock-based compensation expenses of $1.0 million. GAAP net loss attributable to common stockholders was approximately $36.0 million or $(0.52) per common share.
As shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss for the three months ended March 31, 2025, was approximately $11.2 million or $(0.16) per common share.
Lucid had cash and cash equivalents of $25.2 million as of March 31, 2025, compared to $22.4 million as of December 31, 2024. Subsequent to March 31, 2025, the Company completed an underwritten public offering of its common stock for net proceeds of $16.1 million.
The unaudited financial results for the three months ended March 31, 2025, were filed with the SEC on Form 10-Q on May 13, 2025, and available at www.luciddx.com or www.sec.gov.
Lucid Non-GAAP Measures
To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA), and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense and other non-cash income and expenses, if any. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.
Non-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our unaudited financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.
Non-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment, and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.
A reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three months ended March 31, 2025, and 2024 are as follows:
Condensed consolidated statements of operations (unaudited)
(in thousands except per-share amounts)For the three months ended
March 31,
20252024Revenue$ 828$ 1,001Operating expenses13,31511,793
Other (Income) expense14,421(180)
Net Loss(26,908)(10,612)
Net income (loss) per common share, basic and diluted$ (0.52)$ (0.40)
Net loss attributable to common stockholders(36,018)(18,108)
Preferred Stock dividends and deemed dividends9,1107,496
Net income (loss) as reported(26,908)(10,612)
Adjustments:
Depreciation and amortization expense1221501
Interest expense, net2(57)(56)
EBITDA(26,744)(10,167)Other non-cash or financing related expenses:
Stock-based compensation expense31,030933
Operating expenses issued in stock17423
Change in FV convertible debt214,478(291)
Debt extinguishments loss - Senior Secured Convertible Note2—167
Non-GAAP adjusted (loss)$ (11,162)$ (9,335)
Basic and Diluted shares outstanding68,79645,014
Non-GAAP adjusted (loss) income per share$(0.16)$(0.21)1 Included in general and administrative expenses in the financial statements.2 Included in other income and expenses.3 Stock-based compensation ("SBC") expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:
Reconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses
(in thousands except per-share amounts)For the three months ended
March 31,
20252024
Cost of revenues$ 1,551$ 1,656
Stock-based compensation expense3(71)(36)
Net cost of revenues1,4801,620Amortization of intangible assets105372Sales and marketing4,0694,194
Stock-based compensation expense3(239)(350)
Net sales and marketing3,8303,844General and administrative6,1624,070
Depreciation expense(116)(129)
Operating expenses issued in stock(74)(23)
Stock-based compensation expense3(601)(330)
Net general and administrative5,3713,588Research and development1,4281,501
Stock-based compensation expense3(119)(217)
Net research and development1,3091,284Total operating expenses13,31511,793
Depreciation and amortization expense(221)(501)
Operating expenses issued in stock(74)(23)
Stock-based compensation expense3(1,030)(933)
Net operating expenses$ 11,990$ 10,336About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.
Forward-Looking StatementsThis press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2025-financial-results-302455197.html
SOURCE Lucid Diagnostics

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

3 Resilient Retail Stocks That Are Still Growing Amid Tariffs
3 Resilient Retail Stocks That Are Still Growing Amid Tariffs

Yahoo

timean hour ago

  • Yahoo

3 Resilient Retail Stocks That Are Still Growing Amid Tariffs

These companies have generated positive growth in their recent results despite macroeconomic headwinds. These retailers are large and may be better positioned for long-term growth than other companies. 10 stocks we like better than Walmart › The tariff risk is a big one for retailers. It can spike costs significantly for businesses, forcing them to either pass on those increases to consumers, or absorb them, resulting in leaner profits. It's not a great situation, regardless of which way you want to look at it. Some retailers, however, have been demonstrating strong resilience in the face of these threats, in a great sign of their sheer strength. Walmart (NYSE: WMT), Costco Wholesale (NASDAQ: COST), and Dick's Sporting Goods (NYSE: DKS) all posted strong quarterly numbers recently. Does that make them good buys today? Let's take a closer look and find out. On May 15, big-box retailer Walmart released its latest quarterly results, for the period ending April 30. Sales for the quarter totaled $165.6 billion, which were up by 4% when excluding the impact of foreign exchange. And its operating income also rose by more than 4% to $7.1 billion. Around 60% of the company's sales come from its grocery operations, which is why the business may be better suited to handle the effects of tariffs than other retailers. Groceries are necessities that consumers simply can't forgo the way they can with more discretionary purchases when prices rise. And with Walmart offering a vast array of products, it's also a convenient one-stop shop for customers in the event they do want to buy more than just groceries. The retail stock has done well this year, rising by more than 7% in value entering trading this week. At more than 41 times its trailing earnings, it isn't a cheap buy. But if you want stability and are willing to hang on for the long haul, Walmart can be one of the safer and more resilient retail stocks to put in your portfolio right now. Another top retailer that has been doing well of late is Costco. It posted its latest numbers on May 29, and it posted comparable revenue growth of 8% for the period ending May 11. Total revenue of $63.2 billion was up by a similar percentage, while net income of $1.9 billion rose by 13%. The company did say that tariffs have increased its costs and forced it to raise prices in some situations. But consumers can often save money on a per-item basis when shopping at Costco by buying in bulk, and a solid growth rate in the past quarter seems to indicate that's still very much the case. Costco's stock is up 9% this year, but at 57 times its trailing earnings, its valuation has gotten a bit out of hand. And my concern is that if economic conditions worsen, consumers may not be able to afford to buy in bulk, even if it means saving money in the longer term. Cutting out a trip to Costco is an easy way for shoppers to reduce their overall expenditures, and that may end up happening if economic conditions don't improve. When you combine that with an extremely high-priced valuation, you end up with a stock that could be due for a steep correction. As much as I like Costco's business, this isn't a stock I'd buy today, as there's simply too much optimism and bullishness priced into its current valuation. The retail stock that has surprised me the most is Dick's Sporting Goods. The sporting goods retailer is not only doing well and growing, but it's in acquisition mode as well. Recently, it announced plans to buy Foot Locker for $2.4 billion as it looks to reach a broader customer base. And Dick's is already doing well as it is. In its most recent quarter, which ended on May 3, its same-store sales growth was 4.5%, marking the fifth straight quarter where its comparable growth rate was more than 4%. That's a remarkable achievement at a time when consumers are supposedly cutting back on discretionary purchases. The bad news is that the company did experience an 11% decline in its bottom line, with net income falling to $264 million for the period (on net sales of $3.2 billion). The stock has been struggling this year, and it is down more than 20% thus far in 2025 amid macroeconomic concerns. But it trades at just 13 times its trailing earnings and could be a good value buy, especially with it still producing solid growth and looking to enhance its prospects with the acquisition of Foot Locker. While there is some risk here in the short term, given Dick's modest valuation, I think the stock can make a lot of sense as a long-term hold, as it gives investors a good margin of safety at its reduced price. Before you buy stock in Walmart, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Walmart wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Costco Wholesale and Walmart. The Motley Fool has a disclosure policy. 3 Resilient Retail Stocks That Are Still Growing Amid Tariffs was originally published by The Motley Fool

ASICS GT-2160 'Black/Morpho' Delivers Bold Contrast and Retro Appeal
ASICS GT-2160 'Black/Morpho' Delivers Bold Contrast and Retro Appeal

Hypebeast

timean hour ago

  • Hypebeast

ASICS GT-2160 'Black/Morpho' Delivers Bold Contrast and Retro Appeal

Name:ASICS GT-2160 'Black/Morpho'Colorway:'Black/Morpho'SKU:1203A275-003MSRP:$130 USDRelease Date:Available NowWhere to Buy:ASICS TheASICSGT-2160receives a vibrant and intriguing addition with its new 'Black/Morpho' colorway. This iteration continues to pay homage to the technical design language of the GT-2000 series from the early 2010s, while its colorway draws inspiration from the striking black morpho tetra fish. The silhouette combines a stealthy black mesh upper with vivid green and blue overlays, creating a bold visual contrast that highlights the shoe's intricate details. Metallic silver elements are strategically incorporated into the design, further elevating the visual appeal, all sitting atop an off-white sole unit that completes the dynamic look. Emblematic features from the GT-2000 are also carried over, including a segmented midsole structure and visible GEL® technology inserts. This combination not only creates an industrial aesthetic but also provides advanced cushioning properties, enhancing comfort.

KiWear Unveils Smart Ring Input Solution for AI Glasses in Collaboration with Qualcomm at AWE USA 2025
KiWear Unveils Smart Ring Input Solution for AI Glasses in Collaboration with Qualcomm at AWE USA 2025

Yahoo

timean hour ago

  • Yahoo

KiWear Unveils Smart Ring Input Solution for AI Glasses in Collaboration with Qualcomm at AWE USA 2025

Collaboration addresses interactive solutions for smart glasses as global smart glasses shipments surge 210%i year-over-year LONG BEACH, Calif., June 10, 2025--(BUSINESS WIRE)--KiWear, Inc. today announced a reference design for a smart ring input solution for use with smart glasses and AI glasses during Qualcomm Technologies, Inc.'s opening keynote presentation at AWE USA 2025. The collaboration aims to help OEMs develop interactive solutions for AI smart glass partners. Industry analysts expect 60% year-over-year growth in 2025 and a sustained CAGR of over 60% through 2029. "Qualcomm Technologies is fueling the AI glasses industry with our Snapdragon® XR Platforms. KiWear's smart ring, featuring algorithms co-developed with Qualcomm Technologies, makes an ideal input device for smart glasses and AI glasses," said Ziad Asghar, SVP & GM of XR at Qualcomm Technologies, Inc. "This new reference design represents a step forward in helping OEMs to deliver solutions that enable intuitive and discreet gesture based interaction for the growing category of AI smart glasses. "We are thrilled to build next generation input solutions for both AI and XR together with industry leaders such as Qualcomm," said Chris Shi, Founder and CEO of KiWear, Inc. Leading HCI Innovation KiWear, recognized as a leader in HCI innovations, has developed cutting-edge smart ring technology that enables seamless hand-centric interactions with smart glasses and AI glasses. The company's solutions address fundamental input challenges that have limited widespread smart glasses adoption. Founded in April 2025, KiWear is a Delaware-based company delivering comprehensive HCI solutions for multi-DoF controllers, smart rings, and wearables. The company brings together prominent computer vision scientists, AI/XR integration experts, and hardware/software innovators, with expertise spanning conceptualization to mass production. KiWear has forged collaborations and delivers exclusive solutions to six of the global top 10 consumer electronics leaders. With R&D hubs in Shanghai and Beijing beyond its U.S. headquarters, the company partners with premier technology conglomerates to enable natural HCI solutions for next-generation XR and AI products. Live Demonstrations Conference attendees can experience KiWear's smart ring and watch technologies at the Qualcomm Technologies' booth (Booth 209) during AWE USA, showcasing seamless integration with smart glasses platforms. Snapdragon is a trademark or registered trademark of Qualcomm Incorporated. Snapdragon branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. __________________________ i Source: View source version on Contacts Media Contact:Sally GaoKiWear +86-13918187350

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store